Xeris Biopharma Holdings, Inc. (XERS) Covered Calls

You can sell covered calls on Xeris Biopharma Holdings, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for XERS (prices last updated Fri 4:16 PM ET):

Xeris Biopharma Holdings, Inc. (XERS) Stock Quote
Last	Change	Bid	Ask	Volume	P/E	Market Cap
2.92	-0.13	2.92	2.97	1.9M	-	0.5

Covered Calls For Xeris Biopharma Holdings, Inc. (XERS)
Expiration	Strike	Call Bid	Net Debit	Return If Flat	Annualized Return If Flat
Dec 20	2.5	0.40	2.57	-2.7%	-27.4%
Jan 17	2.5	0.45	2.52	-0.8%	-4.6%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls? Sign Up For A Free Trial

Extended Business Description

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.

Top 10 Open Interest For Dec 20 Expiration				Top 5 High Yield
1.	NVDA covered calls	6.	QQQ covered calls	1.	SAVA covered calls
2.	SPY covered calls	7.	XLF covered calls	2.	RKLB covered calls
3.	EEM covered calls	8.	KWEB covered calls	3.	LUNR covered calls
4.	FXI covered calls	9.	TLT covered calls	4.	NMRA covered calls
5.	IWM covered calls	10.	KRE covered calls	5.	CRVS covered calls

Want more examples? XENE Covered Calls | XES Covered Calls